Reactive oxygen species (ROS) have been implicated in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance of many cancers. We evaluated the role of peroxiredoxin (Prx) I in TRAIL resistance governed by coupling of nicotinamide adenosine dinucleotide phosphate oxidase (Nox)-derived ROS signaling with the p38 mitogen-activated protein kinase (MAPK)/ caspase-signaling cascade in liver cancer cells. Upregulated Prx I expression was found in neoplastic regions of human patient liver, and Prx I knockdown resulted in accelerated TRAILinduced cell death in SK-Hep-1 human hepatoma cells. The TRAIL cytotoxicity by Prx I knockdown was dependent on activation of caspase-8/3 cascades, which was ablated by addition of inhibitors for p38 MAPK, ROS or Nox, suggesting the association with Nox-driven redox signaling. Furthermore, we found that Nox4 was constitutively expressed in both SK-Hep-1 cells and tumor regions of patient livers, knockdown of Nox4 expression could alleviate ROS generation and TRAIL-mediated cytotoxicity. In accordance with previous findings, increased activation of both p38 MAPK and caspase cascades by Prx I knockdown was inhibited by either Nox4 knockdown or SB203580 addition. Collectively, these data suggest that Prx I functions to block propagation of Nox-derived ROS signaling to the p38 MAPK/caspase/ cell death cascade during TRAIL treatment and also provides a molecular mechanism by which Prx I contributes to TRAIL resistance in liver cancers.
Introduction
Reactive oxygen species (ROS) act as important signaling molecules in a variety of normal biological events including cell proliferation, differentiation and apoptosis (1) (2) (3) . However, an excess of intracellular ROS has been frequently reported to be associated with cumulative cellular damage in aging, carcinogenesis and degeneration (4) . In addition to the causal relationships between oxidative overload and pathological conditions, recent observations imply that ROS can induce cell death at relatively high concentrations in many cell types, including cancer cells (5) (6) (7) . Based upon these findings, ROS is believed to be a promising therapeutic molecule for oxidative stress-related diseases (8, 9) .
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family of cytokines and induces apoptosis in tumor cells by binding to death receptors (DRs) 4 and 5, which subsequently leads to caspase activation with minimal adverse effects to normal cells (10, 11) . Approximately 65% of tumor cell lines were shown to be sensitive to TRAIL treatment alone, whereas cotreatment with a variety of chemotherapeutic agents has been used to assess any cytotoxic effects on cancer cells, implicating in TRAIL resistance in some tumors (12) . Recently, ROS has been proposed to be an important signaling molecule during TRAILmediated cell death, and modulation of either ROS level (6) or their related pathways appear to improve TRAIL resistance (13, 14) . Increases of ROS result in enhancement of TRAIL antitumor activity (15) , whereas antioxidant treatment ablates TRAIL-mediated cytotoxicity in cancer cells. These observations imply that ROS is involved in TRAIL-mediated cell death.
The five principal nicotinamide adenosine dinucleotide phosphate oxidase (Nox) isozymes are a major source of cellular ROS. Whereas Nox2 expression is phagocyte specific, the other Nox isozymes are expressed in a variety of tissues and cells, including cancer cells (16, 17) . Nox and ROS are both involved in processes mediating cancer progression, such as angiogenesis, metastasis and epithelial-mesenchymal transitions (18, 19) , reflecting the higher ROS demands on cancer cells. In line with augmented ROS levels, cancer cells are generally equipped with well-established antioxidant systems to maintain redox balance under high oxidative stresses; these systems include catalases, glutathione peroxidases and superoxide dismutases. Although an oxidative imbalance causes neoplastic transformation (20) and malignant progression, cancer cell therapy is often improved by increasing the intracellular ROS concentration. Induction of cancer cell death is greatly attenuated when Nox-mediated ROS generation is inhibited (21, 22) or when antioxidant enzymes are upregulated (23, 24) . These findings suggest that redox-signaling pathways governed by Nox-derived ROS and the corresponding neutralizing system are important in the induction of cancer cell death.
Peroxiredoxins (Prxs) are a family of thiol-containing peroxidases identified primarily by their ability to remove cellular hydroperoxides (25) . In addition to their antioxidative roles, Prxs have been implicated in numerous cellular functions including cell proliferation, differentiation and intracellular signaling (26) (27) (28) (29) . Prx I, a member of six isotypes, is characterized by its close association with proliferation (26) and proposed to act as a tumor suppressor from its null mutation study (30) . However, upregulation of Prx I has frequently been found in a variety of cancer cell types, such as liver, lung and thyroid cancers (31) (32) (33) , which obscures its actual role in tumorigenesis. Recently, an increased level of Prx I was reported to be involved in protection of cancer cells against various therapeutic challenges by neutralizing ROS and modulating the related signaling pathways (34, 35) . These findings indicate that Prx I functions as an important regulator of resistance against cancer therapy. However, relatively little is known regarding the underlying molecular mechanisms involved in cancer cell death.
In the present study, we show that Prx I contributes to TRAIL resistance in hepatoma cells by modulating cooperation between Nox4-mediated redox signaling and the caspase-dependent cell death pathways. TRAIL-mediated cell death is highly dependent on Nox4-derived ROS and downregulation of Prx I leads to TRAIL-mediated cytotoxicity. These findings provide a potential molecular mechanism for ROS-dependent TRAIL resistance and may be useful for developing future therapeutic strategies involving TRAIL.
Materials and methods

Antibodies and reagents
The following antibodies were purchased: p38 mitogen-activated protein kinase (MAPK), p-p38 MAPK, caspase-8 (1C12), caspase-3 and cleaved poly (adenosine diphosphate-ribose) polymerase (all from Cell Signaling Technology, Danvers, MA); Nox4 (Santa Cruz Biotechnology, Santa Cruz, CA); mouse monoclonal anti-a-tubulin (Sigma, St Louise, MO); anti-Prx I (Abfrontier, Seoul, Korea) and horseradish peroxidase-conjugated goat anti-rabbit-immunoglobulin G (IgG) and goat anti-mouse-IgG (both from Pierce, Rockford, IL). Human recombinant TRAIL was from Apotech (Epalinges, Switzerland), and Annexin V-FITC Apoptosis Detection Kit I was purchased from BD Pharmingen (San Diego, CA). zVAD-fmk and SB203580 were from Calbiochem (Darmstadt, Germany), and N-acetyl-L-cysteine and diphenyleneiodonium chloride were purchased from Sigma.
Patient tissue samples
Nineteen tissues with paired samples including hepatocellular carcinoma and adjacent non-tumor tissue were collected at the Catholic University of Medicine in Seoul, Korea. All study patients provided informed consents prior to surgery. The hepatocellular carcinomas were classified as grade I (n 5 5), II (n 5 5), III (n 5 5) and IV (n 5 4) according to Edmondson and Steiner.
Transfection of small interfering ribonucleic acids and plasmids SK-Hep-1 cells are a human liver cancer cell line originally obtained from the Korean Cell Line Bank (Seoul, Korea) and routinely cultured in Dulbecco's Modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma) at 37°C in a humidified atmosphere of 5% CO 2 . Cells were transfected with small interfering ribonucleic acids (siRNAs) or plasmids using Lipofectamine RNAi Max (Invitrogen) and Lipofectamine LTX (Invitrogen), respectively, according to the manufacturer's instructions. In brief, 3 Â 10 5 cells were seeded on 60 mm culture dishes and transfected with plasmids or siRNAs using lipofectamine. The cells were harvested by trypsinization at 48-72 h posttransfection, and total RNA and protein were extracted from the cells to determine knockdown efficiency or overexpression, respectively. Target sequences for knockdown of Prx I and Nox4 transcripts were 5#-aaacucaacugccaaguga-3# and 5#-gucaacauccagcuguacc-3#, respectively.
Western blotting
Cells were lysed in lysis buffer A [20 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid (pH 7.5), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 2 mM ethylene glycol tetraacetic acid, 1% Triton X-100, 10% glycerol and protease cocktail I/II (Sigma)], and cellular debris was removed by centrifugation at 15 000 r.p.m. for 10 min. Proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, blocked with 5% skim milk in 0.01 M Tris-buffered saline (TBS; pH 7.5) containing 0.5% Tween 20 and blotted with the appropriate primary antibodies. Membranes were then incubated with horseradish peroxidase-conjugated goat anti-rabbit-IgG or goat anti-mouse-IgG secondary antibodies for 1 h at room temperature and detected by chemiluminescence (Amersham, Uppsala, Sweden).
Semiquantitative RT-PCR Total RNA from tumor tissues, non-tumor tissues and cells was extracted using Trizol reagent (Invitrogen). One microgram of RNA was reverse transcribed using Superscript II (Invitrogen). Reverse transcription-polymerase chain reaction (PCR) was performed using the first strand complementary DNA (1 ll) as template with specific sense (S) or antisense (As) primers for Nox1 (S, 5#-gtacaaattccagtgtgcagaccac-3#; As, 5#-cagactggaatatcggtgacagca-3#), Nox2 (S, 5#-ggagtttcaagatgcgtggaaacta-3#; As, 5#-gccagactcagagttggagatgct-3#), Nox3 (S, 5#-atgaacacctctggggtcagctga-3#; As, 5#-ggatcggagtcactcccttcgctg-3#), Nox4 (S, 5#-ctcagcggaatcaatcagctgtg-3#; As, 5#-agaggaacacgacaatcagccttag-3#), Nox5 (S, 5#-atcaagcggccccctttttttcac-3#; As, 5#-ctcattgtcacactcctcgacagc-3#) and b 2 -microglobulin (b2M; S, 5#-ctcgctccgtggccttag-3#; As, 5#-caaatgcggcatcttcaa-3#). Amplification was carried out using GeneAmp (Applied Biosystems, Foster City, CA) in 10 ll reaction mixtures containing 2 ll of diluted DNA template, 2 pmol of each primer and 2 ll of 5Â premix Ex Taq TM (Genotech, Seoul, Korea) including a deoxynucleoside triphosphate mixture and Mg 2þ , under the following conditions: 95°C for 5 min; followed by 30 cycles at 95°C for 30 s; at 58°C for 30 s and at 72°C for 30 s. b2M was used as a control, and all reactions were performed in triplicate. Melting curves and melting temperatures for each sample were calculated according to the manufacturer's protocol. PCR products were analyzed by 2% agarose gel electrophoresis.
Quantitative real-time PCR Quantitative real-time polymerase chain reaction (qPCR) was performed using the first strand complementary DNA as template and specific primers for Prx I (S, 5#-gacccatgaacattcctttg-3#; As, 5#-aggcttgatggtatcactgc-3#), DR4 (S, 5#-cacacagcaatgggaacata-3#; As, 5#-caacagacaatcagcacagc-3#), DR5 (S, 5#-cctgcaaatatggacaggac-3#; As, 5#-gagcagatgcctttcaggta-3#), five Nox isotypes and the b2M gene. Primers for the Nox isotypes and b2M were identical to those used in semiquantitative reverse transcription-PCR analysis. Amplification was carried out using Exicycler version 2 (Bioneer Co., Daejeon, Korea) in 10 ll reaction mixtures containing 4 ll of diluted DNA template, 2 pmol of each primer and 5 ll of 2Â SYBRÒ Premix Ex Taq TM (TaKaRa Biotechnology Co., Ltd, Shiga, Japan). b2M was used as a control, and all reactions were performed in triplicate. Quantification of relative gene expression was analyzed using the 2ÀDDCt method.
Immunohistochemistry
Patient tissues were fixed overnight with 10% neutral buffered formalin, embedded in paraffin and processed as 5 lm thick sections. Deparaffinized sections were briefly heated for 4 min in a pressure cooker containing 10 mM citrate buffer (pH 6.0) for antigen retrieval. Subsequent procedures were conducted at room temperature. Sections were pretreated with 3% H 2 O 2 in 0.1 M TBS (pH 7.4) for 30 min to quench endogenous peroxidases. The sections were treated with protein block solution (Dako, Carpinteria, CA) for 20 min and incubated with anti-Prx I antibody for 30 min in a humidified chamber. After washing with 0.1 M TBS containing 0.01% Tween 20, sections were incubated with EnVision anti-rabbit (Dako) polymer for 30 min. Peroxidase bound to the antibody complex was visualized by treatment with 3,3#-diaminobenzidine chromogen substrate solution (Dako). The 3,3#-diaminobenzidine reaction was monitored under a microscope to determine optimal incubation time and stopped with several washes of 0.1 M TBS. Immunolabeled sections were dehydrated in a graded ethanol series, defatted in xylene and mounted. Sections were examined with an Olympus BX51 microscope (Olympus, Tokyo, Japan) under bright field, and images were acquired with an Olympus DP 70 camera (Olympus).
Flow cytometry for detection of cell death
To estimate cell death, fluorescein isothiocyanate-conjugated anti-annexin V antibody was labeled in combination with propidium iodide (PI) according to the manufacturer's instructions. Briefly, SK-Hep-1 cells were washed once with phosphate-buffered saline, trypsinized and harvested by centrifugation at 1500 r.p.m. for 3 min. Final cell pellets were stained with annexin Vfluorescein isothiocyanate and PI for 20 min in the supplied incubation buffer, and PI-and/or annexin V-positive cells were analyzed by flow cytometry using FACSCalibur (Becton Dickinson, Franklin Lakes, NJ).
Cell viability assay
Cell viability was determined using a CCK-8 assay kit (Dojindo, Tokyo, Japan) according to the manufacturer's instructions. Briefly, SK-Hep-1 cells were inoculated into a 96-well microtiter plate, and CCK-8 solution (10 ll/100 ll medium) was added to each well of the plate. After incubation of the plate for 1-4 h in a CO 2 incubator at 37°C, the absorbance of each well was measured at 450 nm using a microplate reader (Molecular Devices, Sunnyvale, CA) with a reference wavelength of 650 nm. 
Measurement of intracellular ROS
Results
Upregulation of Prx I in liver cancer cells is involved in resistance against TRAIL-mediated cell death Prx I expression in normal and cancerous human liver tissues was measured by qPCR and immunohistochemistry ( Figure 1 ). Prx I transcript levels were found to be higher in most cancerous tissues than in normal tissues ( Figure 1A) . Similarly, strong immunoreactivity for Prx I was found in neoplastic regions ( Figure 1B , black arrows), indicating that Prx I expression is augmented in human liver cancer.
To investigate the connection of high Prx I levels with TRAIL resistance in liver cancer, we cultured human hepatoma SK-Hep-1 cells and examined the effect of Prx I knockdown on the sensitivity of the cells to recombinant human TRAIL-mediated cell death. SK-Hep-1 cells were transfected with Prx I siRNA (siPrx I), and the level of knockdown was determined by western blot analysis ( Figure  1C ). Approximately 40% of the Prx I protein detected on the control Peroxiredoxin I-dependent TRAIL resistance in liver cancer cells (siCon) was detected in siPrx I-transfected cells. To determine the effect of Prx I knockdown on TRAIL-mediated cell death, siPrx I-transfected SK-Hep-1 cells were cultured for 6 h in the presence of 100 ng/ml TRAIL, labeled with fluorescein isothiocyanateconjugated anti-annexin V antibody and subjected to flow cytometry ( Figure 1D-F) . The live cell population was measured using CCK-8 cell viability assays ( Figure 1E and F) . SK-Hep-1 cells transfected with siPrx I displayed an abrupt dose-and time-dependent ( Figure 1E and F, respectively) increase in cell death with TRAIL treatment, whereas control cells exhibited very little TRAIL-mediated cell death. These results implicate Prx I in TRAIL-mediated cytotoxicity.
Prx I alleviates caspase activation in TRAIL-treated liver cancer cells Caspases are major downstream regulators of TRAIL-mediated apoptosis (36) . To investigate whether caspase activation is involved in the Prx I-dependent response of liver cancer cells to TRAIL-mediated cell death, SK-Hep-1 cells were transfected with either siCon or siPrx I, treated with TRAIL for 4 h and subjected to western blot analysis with anti-caspase-8, caspase-3 and poly (adenosine diphosphateribose) polymerase antibodies (Figure 2A ). Immunoreactive bands for cleaved caspase-8, caspase-3 and poly (adenosine diphosphateribose) polymerase were more intense in siPrx I-transfected cells than those in control cells. However, no apparent differences in the expression of the two TRAIL receptor isotypes, DR4 and DR5, were observed between siCon-and siPrx I-transfected cells during TRAIL treatment ( Figure 2B ), suggesting intracellular cross talk between Prx I-dependent signaling and TRAIL-mediated caspase activation. Next, we examined whether Prx I-dependent caspase activation was involved in TRAIL-mediated liver cancer cell death. To analyze cell death, SK-Hep-1 cells were transfected with siCon or siPrx I, treated with TRAIL in the presence or absence of a potent caspase inhibitor (zVAD-fmk) and subjected to PI/annexin V-based detection of cell death ( Figure 2C ). siPrx I-transfected SK-Hep-1 cells were more sensitive to TRAIL-mediated cell death than siCon-transfected cells, and this effect was completely reversed by addition of zVADfmk, implying active participation of caspase signaling in the Prx I-dependent response to TRAIL.
Prx I inhibits TRAIL-mediated cell death through regulation of redoxsignaling pathways To determine whether redox signaling is involved in the Prx I-dependent response to TRAIL in liver cancer cells, we investigated ROS generation and activation of the related pathway during TRAIL stimulation (Figure 3) . siCon-or siPrx I-transfected SK-Hep-1 cells Ã P , 0.05, ÃÃ P , 0.01). (B) Liver cancer tissue sections were prepared and stained with anti-Prx I antibody. White and black arrows indicate non-neoplastic and neoplastic regions in patient livers, respectively. (C) SK-Hep-1 cells were transfected with siCon and siPrx I and followed by stimulation with 100 ng/ml of TRAIL for 6 h. Knockdown efficiency was determined by western blot analysis using polyclonal Prx I antibody. (D) siCon-or siPrx I-transfected SK-Hep-1 cells were treated with 100 ng/ml TRAIL for 6 h, and cell death was detected using PI/ annexin V. (E and F) After transfection with siCon or siPrx I as indicated, the dose dependence (E) and time dependence (F) of TRAIL exposure on liver cancer cell survival (%; upper panels) and apoptosis (%; lower panels) were quantified using CCK-8 cell viability assays and PI/annexin V, respectively. Values are presented as means ± SDs (n 5 3; Ã P , 0.05; ÃÃ P , 0.01; ÃÃÃ P , 0.001). In (E), cells were exposed to 0-200 ng/ml TRAIL for 6 h. In (F), cells were exposed to 100 ng/ml TRAIL for 0-6 h.
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were treated with TRAIL for 15 min, incubated with 10 lM of CM-H 2 DCFDA (a ROS indicator) for 5 min and analyzed using fluorescence microscopy ( Figure 3A ) and flow cytometry ( Figure 3B ). Unlike siCon-transfected cells, siPrx I-transfected cells displayed a significant increase in 2#,7#-dichlorofluorescein intensity, which was further enhanced by TRAIL treatment. We next examined activation of MAPK-signaling pathways, representative redox-dependent signaling cascades, under conditions of increased intracellular ROS levels. siCon-or siPrx I-transfected SK-Hep-1 cells were treated with TRAIL for 4 h, sampled at different treatment times and subjected to western blot analysis with anti-p-p38 MAPK and p38 MAPK antibodies ( Figure 3C ). Prx I expression remained unchanged throughout TRAIL treatment, although Prx I protein levels were effectively knocked down by siPrx I transfection ( Figure 3C, upper blots) . Phosphorylated p38 MAPK levels were slightly increased during TRAIL treatment in siCon-transfected cells, whereas siPrx I-transfected cells showed more increase under the same stimulation condition ( Figure  3C , lower blots). These results indicate that redox signaling is regulated by Prx I in liver cancer cells treated with TRAIL.
To further investigate the role of both ROS and p38 MAPK in TRAIL-induced cell death, SK-Hep-1 cells were transfected with either siCon or siPrx I, treated with TRAIL for 6 h in the presence or absence of inhibitors for caspase (zVAD-fmk), p38 MAPK (SB203580), ROS (N-acetyl-L-cysteine) and Nox (diphenyleneiodonium chloride) and subjected to flow cytometry for detection of cell death ( Figure 3D) . A higher level of cell death was seen in Prx I-transfected cells than in control cells. This effect was alleviated by treatment with zVAD-fmk, SB203580, N-acetyl-L-cysteine and diphenyleneiodonium chloride, suggesting that TRAIL-mediated liver cancer cell death involves coordination among caspases, p38 MAPK and ROS-dependent pathways.
Prx I protects liver cancer cells from TRAIL-mediated cell death by neutralization of Nox4-driven ROS To clarify whether Nox-mediated ROS generation contributes to TRAIL sensitivity in liver cancer cells, we identified Nox isotypes highly expressed in liver cancer cells by reverse transcription-PCR and determined the sensitivity to TRAIL-mediated cell death in transfected cells (Figure 4) . Although transcripts for Nox2, Nox4 and Nox5 were amplified by qPCR from both normal and tumor tissues, only Nox4 was dramatically overexpressed in tumors ( Figure 4A ). Similarly, we found that of the three Nox isotypes, Nox4 expression predominated in SK-Hep-1 cells, regardless of Prx I levels ( Figure 4B ). Thus, siNox4 and siPrx I were cotransfected into liver cancer cells, and knockdown efficiency was determined by western blot and qPCR analyses of Nox4 and Prx I mRNA and protein levels. Nox4 and Prx I protein expression were significantly reduced by transfection of the respective siRNA ( Figure 4C) , and Nox4 and Prx I mRNA levels were decreased by $90 and 70%, respectively ( Figure 4D 
Peroxiredoxin I-dependent TRAIL resistance in liver cancer
Under both basal and TRAIL-treated conditions, levels of ROS were higher in siPrx I-transfected cells than in siCon-transfected cells, and this effect was largely abrogated by siNox4 cotransfection ( Figure 4E and F), suggesting that Prx I neutralizes ROS generated by Nox4 in liver cancer cells. Our results reveal that intracellular ROS levels are closely associated with TRAIL-mediated liver cancer cell death and that Nox4 and Prx I actively balance oxidant levels during this process. Therefore, we subsequently examined whether Nox4 knockdown contributes to reduction of TRAIL-mediated cell death in liver cancer cells ( Figure 5 ). siPrx I-and/or siNox4-transfected SK-Hep-1 cells were treated with TRAIL for 4 h and probed with anti-caspase-3 and cleaved caspase-3 antibodies ( Figure 5A ). Increased levels of cleaved caspase-3 were found in siPrx I-transfected cells compared with those in siCon-transfected cells. The original levels were restored, however, with either the addition of SB203580 or siNox4 transfection in siPrx I-transfected cells, implicating Nox4 and p38 MAPK as upstream regulators of caspase-3 activation ( Figure 5A) . A relationship between Nox4 and p38 MAPK was suggested from western blot results for anti-p38 and pp38 MAPK antibodies after knockdown of Nox4 and/or Prx I ( Figure  5B ). Increase of p38 MAPK phosphorylation in siPrx I-transfected cells was alleviated by siNox4 knockdown, suggesting the involvement of Nox4-derived ROS in activation of the p38 MAPK signal pathway. Similarly, the effect of Prx I knockdown on TRAIL-mediated cell death or survival was abolished by transfection with siNox4 or addition of SB203580 ( Figure 5C ). Collectively, these results suggest that TRAIL-induced caspase-3 activation is highly dependent on p38 MAPK-signaling pathways governed by the coordinate action of Nox4 and Prx I.
Discussion
We have shown that high levels of Prx I contribute to resistance of TRAIL-induced cell death through inhibition of Nox4-mediated signaling pathways in liver cancer. These findings allow us to propose a comprehensive model for the role of Prx I in TRAIL-mediated cell death ( Figure 6 ). When TRAIL binds to its membrane-bound DR4/5 receptor, procaspase-8 is recruited, binds to the cytoplasmic domain of DR4/5 and cleaves procaspcase-8 into activated caspase-8. Cleaved caspase-8 then activates procaspase-3, which initiates cells to undergo apoptosis. During this process, Nox4-derived ROS actively participate in p38 MAPK-dependent caspase-8/3 activation. However, both pathways are inhibited by neutralization of ROS with high Prx I concentrations, leading to TRAIL resistance. On the contrary, liver cancer cells with reduced Prx I levels fail to scavenge intracellular ROS under TRAIL stimulation, and the resulting excess of ROS accelerates activation of caspase-8 and p38 MAPK. Thus, caspase-3-dependent apoptosis is synergistically enhanced by activation of both pathways, and liver cancer cells is released ultimately from TRAIL resistance.
Deletion of the mouse tumor suppressor Prx I causes high frequency, age-dependent carcinogenesis (30) and increases oxidative DNA damage in fibroblasts (37) . Although Prx I, unlike other tumor suppressors, can be detected at high levels in numerous cancers (31-33), its role in tumor cells has not been precisely determined. Recently I.-S.Song et al.
reported evidence suggests that a Prx-mediated ROS-sensing mechanism is important in tumor cell resistance to numeral tumor therapy, including radiation. Upon exposure of tumor cells to an oxidative stimulus such as ionizing radiation, Aplysia ink toxin or 6-hydroxydopamine, Prx I actively protects the cells by blocking redox-sensitive signaling pathways involving c-jun N-terminal kinase and p38 MAPK (34, 35, 38) . Under oxidative conditions, Prxs are readily overoxidized as a result of their active involvement in neutralization of intracellular ROS (39, 40) , which contributes to cellular resistance to the redox-induced cell death pathway. Thus, SO 2/3 formation at the catalytic cysteine residue of Prx indirectly reflects its role as a ROS scavenger. We found that TRAIL treatment causes SO 2/3 formation by Prx I, and the overoxidation of Prx I caused by H 2 O 2 pretreatment can release SK-Hep-1 cells from their TRAIL resistance (supplementary Figure 1 is available at Carcinogenesis Online). These results suggest Western blot (C) and qPCR (D) analyses were carried out to determine the knockdown effect of siPrx I and siNox4 cotransfection. Nox4 transcript levels were quantified, and the values are presented as means ± SDs (D, n 5 3;
Ã P , 0.01, ÃÃ P , 0.001). (E and F) Cells transfected with siPrx I and/or siNox4 were incubated with CM-H 2 DCFDA, and ROS generation was determined by fluorescence microscopy (E) or flow cytometry (F, upper panel). ROS intensities were quantified (F, lower panel), and the values are presented as means ± SDs (n 5 3;
Ã P , 0.05; ÃÃ P , 0.01; ÃÃÃ P , 0.001).
Peroxiredoxin I-dependent TRAIL resistance in liver cancer that the TRAIL resistance mechanism of liver cancer cells requires the peroxidase activity of Prx I. Although why Prx I is upregulated during tumorigenesis is unclear, and its functions at various ontogenic cancer stages are unclear as well, the high level of Prx I in cancer cells has impeded the development of effective cancer therapies. Thus, the success of recombinant TRAIL as a therapeutic modality in patients with liver cancer may hinge on the development of an effective strategy for reducing the expression or enzymatic activity of Prx I. TRAIL binds DR4 and DR5 to induce caspase-dependent apoptosis. However, decoy TRAIL receptors (DcR1 and DcR2) do not activate apoptosis due to the absence of the cytoplasmic death receptor domain. Thus, expression of DR4 and DR5 is often critical to TRAILmediated cytotoxicity (41, 42) . The transcriptional activation of the receptors is often triggered by oxidants such as H 2 O 2 (41), indicating an alternate mode of ROS action during TRAIL-mediated cell death. Consistent with this conjecture, the effects of various therapeutic agents, including anticancer drugs (43) and plant-derived chemicals (13, 44) , on the sensitization of hepatoma cells to TRAIL is tightly associated with ROS-dependent DR5 upregulation, which itself is ablated by pretreatment with chemical antioxidants or by overexpression of antioxidant enzymes (13) . These findings suggest that combining TRAIL with redox-regulating agents capable of upregulating DR5 might sensitize tumors to TRAIL-induced cell death. However, we found that DR4 and DR5 are consistently expressed during TRAIL treatment, regardless of Prx I levels. Therefore, local ROS concentrations governed by Prx I might be directly involved in activation of the caspase-signaling cascade.
Caspases are a specialized family of proteases that carry out apoptosis by destroying structural and functional cellular proteins (36) . Activation of caspases is generally known to be related to oxidative status, but the underlying mechanisms are not yet clearly determined. Recent evidence suggests that MAPK family members play a role in activating caspase-signaling cascades (38, 45) . During tumor cell death, MAPK activation seems to act as a bridge between ROS and caspase cascades. Among the MAPK members, p38 MAPK signaling is often linked to activation of caspase-8 (46) , an important component of the death-inducing signaling complex (42) . Similarly, here, p38 MAPK was identified as a modulator of TRAIL/caspase-8/caspase-3-dependent cell death (Figures 3 and 5) . Phosphorylation of p38 MAPK precedes cleavage of procaspase-8 and inhibition of p38 MAPK ablates both caspase-signaling cascades and TRAIL-mediated cytotoxicity. Therefore, p38 MAPK pathway is proposed as a ROSsensing route for the activation of caspase-8 in death-inducing signaling complex formed during treatment with TRAIL.
MAPK signaling mediates the cellular response to mitogens or other stresses and alters cellular behaviors, such as proliferation and apoptosis, and ROS is considered to be a factor in the activation of MAPKs (47) . Accordingly, the activation of MAPKs is regulated by the harmonized action between ROS generation and its neutralizing system. Although c-jun N-terminal kinase and p38 MAPK were immediately activated by TRAIL in siPrx I-transfected cells (data not shown), SB203580, but not SP600125, displayed antiapoptotic activities by blocking TRAIL-induced caspase activation. These findings imply that TRAIL resistance in liver cancer cells is derived from Prx Ã P , 0.05; ÃÃ P , 0.01 and ÃÃÃ P , 0.001).
I-mediated neutralization of ROS, which is linked to phosphorylation of p38 MAPK. Similarly, recent studies showed that ROS-mediated p38 MAPK activation is blocked by Prx I overexpression (40, 48) . Moreover, Prx I appears to inhibit p38 MAPK-dependent caspase-8 activation by neutralizing ROS during 6-hydroxydopamine-mediated dopaminergic neuronal cell death. Therefore, these results suggest that coupling of Prx I peroxidase activity and p38 MAPK signaling are essential for ROSdependent caspase activation and subsequent cell death. Patterns of MAPK activation may be involved in the cell survival/ death decision (49) . Under oxidative conditions, cell survival and death are tightly correlated with early/transient and late/sustained activation, respectively, of c-jun N-terminal kinase and p38 (50) (51) (52) , indicating that oxidative cell death may depend on the extent or duration of MAPK activation. In the current study, the basal level of p38 phosphorylation was slightly elevated in siPrx I-transfected cells compared with control cells. ROS escaping from Prx I-mediated antioxidative surveillance might have caused the slight increase in p38 phosphorylation. However, we found no differences in cellular behaviors involving cell death when the basal level of p38 activation was increased; TRAIL-mediated cell death was only detected when p38 phosphorylation was sustained above the basal level. Although we did not address the direct evidence of a relationship between sustained p38 phosphorylation and caspase activation in our study, the sensitivity of liver cancer cells to TRAIL might be increased by cross talk between sustained p38 phosphorylation and caspase activation.
Taken together, our findings propose that Prx I acts as a modifier in redox-signaling pathways, leading to activation of the Nox/p38/caspase-signaling cascade during TRAIL-induced liver cancer cell death. Furthermore, our findings explain why Prx I is highly expressed in liver cancers. The underlying mechanisms will provide a fundamental basis for a therapeutic modality in TRAIL-mediated cancer therapy.
Further studies include examining potential candidates linking Prx I to the Nox/p38/caspase-signaling cascades and examining the effect of Prx I on TRAIL-mediated cancer regression in related mouse models. 
